The vaccine developer Genocea Biosciences has used its in-house proteomics screening technology, AnTigen Lead Acquisition System (ATLAS), to identify two potential candidates for C trachomatis vaccines.
GSK has opted to buy out the company for $98 million, snagging full rights to a pair of early-stage inflammation programs and a proteomics technology.
Startup Integrated Diagnostics has reeled in another $10 million to fuel further clinical work on its in vitro proteomic-based diagnostics programs, with an eye toward hitting the commercial market...
A group of 13 proteomics service companies and providers have banded together to create the Proteomics Innovation Network. Its stated mission is to generate "from sample to discovery" solutions in
Federal funding is furthering research in two areas: DNA sequencing and proteomics. First, The National Heart, Lung, and Blood Institute has allocated $64 million in American Recovery and